Skip to main content
. 2015 Apr 14;21(14):4240–4247. doi: 10.3748/wjg.v21.i14.4240

Table 2.

Associations of MMS19 expression with clinicopathologic features of esophageal squamous cell carcinoma

Characteristic Cases (n) Cytoplasmic MMS19
Nuclear MMS19
High Low P value High Low P value
Total 103 65 38 36 67
Sex
Male 84 55 29 0.295 32 52 0.159
Female 19 10 9 4 15
Age (yr)
< 55 33 18 15 0.216 14 19 0.275
≥ 55 70 47 23 22 48
Site
Upper thoracic 10 7 3 0.686 2 8 0.508
Middle thoracic 47 31 16 16 31
Lower thoracic 46 27 19 18 28
Differentiation
Well 20 13 7 0.785 6 14 0.871
Moderate 52 34 18 19 33
Poor 31 18 13 11 20
TNM stage
I + II 27 14 13 0.158 8 19 0.500
III + IV 76 51 25 28 48
Invasion depth
T1 + T2 25 17 8 0.560 7 18 0.402
T3 + T4 78 48 30 29 49
LNM
No 12 2 10 < 0.001 4 8 0.900
Yes 91 63 28 32 59
DM
No 85 48 37 0.002 32 53 0.212
Yes 18 17 1 4 14

DM: Distant metastases; ESCC: Esophageal squamous cell carcinoma; High: Including composite score of 6, 8, 9 and 12; LNM: Lymph node metastases; Low: Including composite score of 0, 1, 2, 3 and 4; MMS19: methyl-methanesulfonate sensitivity 19.